Revvity Signals Banner Ad (Nov-Dec)

AI-Powered Pharmaceutical Quality Control

Lakshmi, Editorial Team, Pharma Focus America

Pharmaceutical quality control remains one of the most labor-intensive and compliance-sensitive stages of drug manufacturing. Artificial intelligence (AI) is increasingly being applied to automated visual inspection, real-time spectral analysis, deviation triage and batch record review, promising faster release and fewer quality failures. This article reviews the leading applications of AI in pharmaceutical quality control, outlines the FDA's emerging regulatory expectations, and examines a 2026 warning letter that exposed the risks of unvalidated AI use. It concludes that sustainable value depends on validated models, strong data governance and clear human accountability within the quality system.

Introducing the Pharmaceutical Quality Problem AI Was Built to Solve

Every finished batch of medicine in America waits for a signature. Before it ships, a quality unit must be satisfied that the product is what the label says it is, at the strength it claims, free of contamination and made the way the approved process demands. That signature carries legal weight, and it rests on a mountain of evidence: test results, inspection records, environmental data, investigation reports and thousands of entries in electronic batch records.

For decades, that evidence has been gathered and checked largely by hand. Skilled analysts run assays, trained inspectors stare at vials under controlled light, and reviewers page through records looking for the one entry that does not belong. The system works, but it is slow, expensive and only as consistent as the people inside it on a given shift.

Artificial intelligence is changing that equation. Machine learning models can now flag a cosmetic defect in a syringe, predict an out-of-specification result before the lab confirms it and sort hundreds of deviation reports by genuine risk. For pharmaceutical leaders, the promise is compelling: faster release, fewer recalls and quality teams freed to focus on judgment rather than paperwork. The question is no longer whether AI belongs in quality control. It is how to deploy it without creating a new category of compliance risk.

Why Traditional Quality Control Is Running Out of Road

The pressure on quality operations is visible in the FDA's own enforcement record. A review of 85 warning letters issued to drug manufacturers in 2025 found that the most frequently cited problems were basic ones: inadequate identity testing of incoming components, insufficient testing for purity and strength, procedures that were not validated or followed, and weak investigation of failures. Quality unit responsibilities were cited dozens of times. Data integrity concerns appeared in about 15 percent of the letters, with sharp differences by region.

Those findings point to a structural problem rather than a lack of effort. Product portfolios are more complex, with biologics, sterile injectables and combination products demanding more testing per batch. Experienced quality professionals are hard to recruit and harder to retain. Meanwhile, supply chains stretch across continents, multiplying the number of suppliers whose materials must be verified.

Manual review struggles at that scale. Investigations pile up, release times lengthen, and the same root causes surface again because no one has the bandwidth to connect patterns across sites and years. AI does not remove those pressures, but it gives quality teams a way to see more, sooner, with the people they already have.

Where AI Is Already Earning Its Place on the Quality Floor

The most mature application is automated visual inspection. Sterile injectables must be checked for particles, cracks, cosmetic flaws and fill-level problems. Traditional rule-based camera systems tend to reject good units to stay safe, wasting expensive product. Deep learning models trained on large libraries of defect images can distinguish a harmless air bubble from a glass particle with greater consistency, and manufacturers are increasingly validating them for production use.

In the laboratory, machine learning is extending process analytical technology. Models that interpret near-infrared and Raman spectra in real time allow manufacturers to monitor blend uniformity, moisture or concentration during production rather than waiting for end-of-line tests. Over time, that capability supports a move toward real-time release, where quality is demonstrated continuously instead of retrospectively.

Some of the fastest returns come from less glamorous work. Natural language processing tools can read deviation reports, complaints and corrective action records, cluster them by likely root cause and highlight recurring issues across facilities. Review-by-exception systems scan electronic batch records and route only the anomalies to human reviewers. Predictive models applied to environmental monitoring and equipment data can warn of contamination risk or instrument drift before a batch is compromised.

The FDA's Evolving Rulebook for AI in Pharmaceutical Quality

Regulators have signaled openness rather than resistance, paired with a clear expectation of control. In January 2025, the FDA issued draft guidance on using artificial intelligence to support regulatory decision-making for drugs and biologics, built around a risk-based framework for establishing a model's credibility for its intended use. The agency's Center for Drug Evaluation and Research has also studied AI in manufacturing through its advanced manufacturing initiatives and public discussion papers, and listed AI and machine learning quality considerations in pharmaceutical manufacturing on its 2026 guidance agenda.

International alignment is moving in parallel. In January 2026, the FDA and the European Medicines Agency jointly published guiding principles for good AI practice across the medicines lifecycle, covering themes such as risk-based design, data quality, transparency and lifecycle monitoring. For companies that manufacture for both markets, that convergence is welcome news.

The underlying message is consistent. Existing current good manufacturing practice rules still apply in full. An AI model that influences a quality decision must be fit for purpose, validated, documented and monitored, and accountability stays with people.

Case Study: The Warning Letter That Put AI Quality Control on Notice

In April 2026, the FDA issued what legal analysts described as the first warning letter centered on the misuse of AI in drug manufacturing. The facts are instructive precisely because they are so ordinary.

According to published analyses of the letter, the manufacturer had relied on AI agents to draft core compliance documents, including product specifications, procedures and master production records. When investigators questioned gaps in its practices, staff explained that they had not known about certain legal requirements because the AI tool had not flagged them. The firm had also distributed products without completing required process validation, again citing the tool's silence.

The FDA's response was unambiguous. It cited the requirement that the quality unit approve or reject every procedure and specification affecting a drug's identity, strength, quality or purity, and stated that AI-generated outputs must be reviewed and approved by an authorized quality representative. It also cited failures to establish and follow written production and process controls. The agency did not ban the use of AI. It made clear that responsibility for compliance cannot be handed to software.

For executives, the lesson is uncomfortable but useful. The risk in AI quality control is less about a model making an exotic error and more about an organization quietly lowering its guard because a tool appears authoritative. Governance failures, not algorithm failures, triggered this letter.

Building an AI Quality Control Program That Survives an Inspection

Successful programs start with intended use. Each model should have a defined job, a defined risk level and a defined owner. A tool that sorts complaint records for faster triage carries far less risk than one that accepts or rejects finished vials, and validation effort should scale accordingly.

Data comes next. Models learn from historical records, so incomplete, inconsistent or poorly governed data will quietly undermine results. Investment in data integrity, standardized formats and traceable lineage pays off twice: it improves model performance and strengthens the evidence package an investigator will ask to see.

Human oversight must be designed in, not added later. That means clear rules on when a model's recommendation is final, when it requires review and how disagreements between people and algorithms are recorded. It also means monitoring performance after go-live, because a model trained on last year's defects may drift when a new supplier, line or product arrives.

Finally, people need new skills. Quality professionals do not have to become data scientists, but they must understand what a model is doing well enough to challenge it. Organizations that pair quality, IT and data science teams early tend to avoid the costly rework that follows a siloed rollout.

Making the Business Case for AI in Pharmaceutical Quality

Boards will rightly ask about return on investment, and the answer is broader than labor savings. Faster batch release frees working capital tied up in inventory awaiting approval. Fewer false rejects in visual inspection recover sellable product, which matters enormously for high-value biologics. Earlier detection of process drift reduces the chance of a failed batch, a recall or a supply shortage that damages relationships with patients, payers and regulators.

There is also a strategic dimension. As domestic manufacturing investment grows across the United States, new and expanded facilities have a rare opportunity to build AI-ready quality systems from day one rather than retrofitting legacy plants. Companies that seize it will set the operating benchmark others must chase.

Concluding Thoughts on AI and the Future of Pharmaceutical Quality

AI-powered quality control is no longer an experiment confined to innovation labs. It is inspecting products, reading data and shaping decisions on manufacturing floors today, and regulators on both sides of the Atlantic have set out how they expect it to be governed.

The opportunity for American pharmaceutical leaders is significant: quicker release, steadier supply and quality teams that spend their expertise where it matters most. The obligation is equally clear. Every algorithm must be validated for its job, monitored over its life and answerable to a qualified human being.

Technology can inspect a million vials without blinking. It still cannot sign the batch record. The companies that keep that distinction sharp will turn AI from a compliance risk into a lasting quality advantage.

Lakshmi

Lakshmi is a science writer with a foundation in the laboratory. She earned her master's in biotechnology and trained through research internships at ICGEB (JNU) and DIPAS, DRDO, with her work appearing in the Egyptian Journal of Veterinary Sciences. Now APCRM-certified and part of the editorial team at Pharma Focus America and Pharma Focus Europe, she reports on pharmaceutical technology, research, and innovation — giving complex science a clear and confident voice for industry leaders.